Navigation Links
C3i Inc to Provide Full-Service Technology Support and Oracle Clinical, Oracle Remote Data Capture Business Process Outsourcing to XBiotech, Inc
Date:6/2/2011

MORRISTOWN, N.J., June 2, 2011 /PRNewswire/ -- C3i, a world leader in clinical trial support services, today announced the signing of its newest client, XBiotech, Inc. XBiotech, located in Austin, TX, is a leader in the development of therapeutic antibodies, and has launched the first "True Human" monoclonal antibody into clinical trials. XBiotech's lead drug candidate uniquely blocks pathologic inflammatory responses and is being developed to treat diseases such as cancer, atherosclerosis, and diabetes. C3i, a Gold level member in Oracle PartnerNetwork (OPN), will provide a full-service technical solution to support its program of promising clinical trials.

Leveraging its proprietary help desk support and end user training systems, in conjunction with Oracle's market-leading Oracle Clinical and Oracle Remote Data Capture clinical data management system, C3i provides a turnkey solution to meet the needs of scientifically focused organizations like XBiotech.

C3i will provide XBiotech with global site training and support services to enable participating clinical sites to rapidly become proficient in the use of Oracle Remote Data Capture, a leading data capture solution that allows clinical site personnel to collect study patients' data at the investigator site and facilitates higher quality data.

XBiotech required a world-class data management system on which to build and manage its clinical trials and the support of consultants with the technical expertise and industry experience necessary to get their trials up and running quickly.

"C3i's comprehensive services combined with Oracle Health Sciences solutions provide us with the opportunity to manage our clinical data in a top-tier system, that is hosted and operated with expertise and experience," said Michael Stecher M.D., XBiotech's Medical Director.

"We are excited to welcome a growing company like XBiotech as a client. We believe they exemplify the still emerging potential of the important biotech industry." added Joel Morse, C3i's CEO. "Our business process outsourcing solution is well-suited to XBiotech's current data management and IT requirements, and provides them with a flexible model to accommodate their growth."

Tyler Prince, group vice president, North America Sales, Applications and Public Sector Alliances & Channels, Oracle pointed out that "C3i's full range of tailored services illustrate the value that Oracle partners bring to our joint customers."

About C3i: Headquartered in Morristown, New Jersey, C3i Inc. has global operations in North America, Europe, India and China. Their 1200 employees provide systems implementation, technology training, multi-lingual help desk, hardware provisioning, and break/fix, asset management, and user/application administration services for pharmaceutical sales and clinical professionals worldwide. To learn more, visit www.c3i-inc.com.

C3i is a Gold-level member of Oracle® PartnerNetwork.

About XBiotech: XBiotech, located in Austin, TX, is a leader in the development of therapeutic antibodies, and has launched the first "True Human" monoclonal antibody into clinical trials. XBiotech's lead drug candidate uniquely blocks pathologic inflammatory responses and is being developed to treat diseases such as cancer, atherosclerosis, and diabetes. To learn more, visit www.xbiotech.com

Trademarks

Oracle and Java are registered trademarks of Oracle and/or its affiliates.

Contact:

Dave Hanaman
C3i Inc
973-401-4677
dhanaman@c3i-inc.com


'/>"/>
SOURCE C3i
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Physicians Growing Demand for Point-of-Care Resources Spawns iPointOfCare From Top Continuing Medical Education Provider; DIME
2. St. Lukes Hospital & Health Network Selects CareTech Solutions to Provide Proactive Monitoring of Hospital IT Infrastructure
3. Juventas Therapeutics Demonstrates JVS-100 Delivery to Patients with Heart Failure is Safe and Provides Clinical Benefit
4. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
5. Neuralstem Reports First Quarter Financial Results and Provides Business and Clinical Update
6. Tengion to Host Conference Call to Provide a Business Update and Report First Quarter 2011 Financial Results on May 12, 2011
7. Clinical Site Services Expands to Provide Global Patient Enrollment Services to Rest-of-World
8. Understanding how glasses relax provides some relief for manufacturers
9. ERT Awarded over $10 Million of ePRO Business from Major Pharma - Increasing its Position as a Leading ePRO Provider
10. Magellan Biosciences Announces Agreement with Bruker to Provide Microbiology Tools to Battle Drug Resistance
11. New model of whiskers provides insight into sense of touch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
(Date:6/23/2016)... ... 23, 2016 , ... ClinCapture, the only free validated electronic ... showcase its product’s latest features from June 26 to June 30, 2016 for ... Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug Information ...
Breaking Biology Technology:
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
(Date:3/31/2016)... March 31, 2016  Genomics firm Nabsys has completed ... Barrett Bready , M.D., who returned to the ... original technical leadership team, including Chief Technology Officer, ... Development, Steve Nurnberg and Vice President of Software and ... company. Dr. Bready served as CEO of ...
Breaking Biology News(10 mins):